Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX) reported statistically significant effectiveness from a pivotal field trial of crofelemer (conditionally approved Canalevia-CA1) for chemotherapy-induced diarrhea (CID) in dogs. Dogs treated twice daily showed an average daily stool regarded as normal after three days. Owner surveys: 83% found treatment effective; ~40% reported complete resolution. Comparator: 12.5% of owners reported improvement without CID treatments. Jaguar expects to file full trial data to support a full FDA approval and pursue scientific publication.
Jaguar Health (Nasdaq: JAGX) received a Nasdaq Hearings Panel extension to May 15, 2026, to demonstrate compliance with the $1.00 bid price rule and announced a 1-for-35 reverse stock split effective April 30, 2026. The company said post-split shares will trade on a split-adjusted basis under symbol JAGX and will use new CUSIP 47010C862. Stockholders of record will receive exchange instructions from Equiniti Trust Company; brokerage-held shares require no action. Fractional shares will be cash‑settled.
Jaguar Health (NASDAQ: JAGX) family company Napo announced acceptance of two late-breaking abstracts at ESPGHAN for liquid oral crofelemer treating pediatric intestinal failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS).
Company reports crofelemer was well tolerated, associated with reductions in parenteral support (PS) and gains in weight/height in treated pediatric patients; orphan drug designations exist in the US and EU and a pediatric randomized MVID trial completed enrollment with an NDA planned mid-2027.
Jaguar Health (NASDAQ:JAGX) announced that stockholders approved all five proposals at its Special Meeting held April 20, 2026. The proposals are described in the definitive proxy statement on Schedule 14A filed March 24, 2026. Stockholders can obtain the proxy and related SEC filings for free at the SEC website or the company website.
Jaguar Health (NASDAQ:JAGX) plans to leverage AI platforms to support development, commercialization, and healthcare delivery for crofelemer in intestinal failure (IF) including pediatric MVID.
Key points: an investigator-sponsored MVID program showed up to 37% reduction in parenteral support; Jaguar is pursuing Breakthrough Therapy designation and is seeking non-dilutive partner funding to accelerate approval and access.
Jaguar Health (NASDAQ:JAGX) will host an investor webcast on Friday, April 10, 2026 at 8:30 a.m. Eastern to discuss Q4 2025 financials and company updates.
Participant registration is available via the company’s registration link and a replay will be posted on Jaguar Health’s investor relations website.
Jaguar Health (NASDAQ:JAGX) completed its effectiveness study of Canalevia-CA1 (crofelemer) for chemotherapy-induced diarrhea (CID) in dogs and expects topline results within a month. The FDA renewed conditional approval through Dec 21, 2026; Jaguar plans to file effectiveness results in Q2 2026 to seek full approval.
A prior 28-day neratinib study showed a 30% reduction in incidence and severity of diarrhea, reported as statistically significant.
Jaguar Health (NASDAQ:JAGX) reported Q4 2025 consolidated results on April 7, 2026. Total net revenue was approximately $3.2M in Q4, up 5% sequentially and down ~8% year-over-year. For full-year 2025 net product revenue was $11.5M. Jaguar received a $16.0M up-front, non-dilutive license payment in January 2026 from Future Pak and will recognize manufacturing revenue under the U.S. license agreement.
Jaguar recorded increased R&D and operating losses, with a 2025 net loss attributable to common shareholders of $53.6M and a loss from operations of $45.9M. Nasdaq delisting proceedings remain stayed pending an April 7, 2026 hearing.
Jaguar Health (NASDAQ:JAGX) family company Napo is a silver sponsor of the April 2-4, 2026 Elite Ped-GI Congress in Abu Dhabi and is supporting an investigator-initiated proof-of-concept study of crofelemer liquid in pediatric intestinal failure (IF) patients with MVID and SBS-IF.
The study reported parenteral support (PS) reductions of 12–37% in ongoing patients treated >1 year; an abstract on long-term safety and efficacy was submitted for ESPGHAN June 2026. The global SBS/IF market is estimated at $8.0 billion by 2033.
Jaguar Health (NASDAQ:JAGX) said FDA feedback supports a protocol amendment to permit a single-blind extension of Napo's crofelemer trial in pediatric microvillus inclusion disease (MVID). The extension aims to assess longer-term clinical benefit by reducing parenteral support (PS), with dose selection by an independent DMC.
Approximately 30% of patients have completed the double-blind phase; sites include the US, Italy and UAE. Company highlighted potential for a Breakthrough Therapy designation to enable expedited pathways.